11Beta-HSD1
inhibitors appear to be attractive R&D products for the treatment
of type 2 diabetes, because a large number of major biotechnology and
pharmaceutical companies are involved in their development, and this
pipeline, although very young, already has 70% of products in clinical
stage of development., according to a new report, titled Diabetes
R&D Pipeline: 11beta-HSD1 inhibitors, added to the offering of
Research and Markets.
11Beta-HSD1
(11beta-hydroxysteroid dehydrogenase type 1) antagonists are insulin
sensitizers. 11beta-HSD1 is an enzyme that converts inactive cortisone
into potent, biologically active hormone, cortisol. This conversion
occurs within cells of key metabolic tissues including liver, adipose
tissue, muscle tissue, and pancreas. Cortisol elevates blood glucose
levels by increasing glucose production in liver, and by inhibiting
uptake and disposal of glucose in muscle and adipose tissues.
More about: 11Beta-HSD1 sale
Read more: Proteases Enzyme
No comments:
Post a Comment